Omeros Corporation (OMER)

Omeros faces a second European setback after regulators upheld a negative opinion on narsoplimab for transplant-associated thrombotic microangiopathy. The company’s U.S. launch remains the central growth driver, supported by $28.5 million in Q2 net sales, while Europe’s rejection limits international expansion. OMER is down 2.11% today on a full-day basis, with the market open.